592542-51-3

Basic information

• Product Name: 4-Methoxy-3-nitrobenzylsulfonylacetic acid
• Synonyms: 3-NITRO-4-METHOXYBENZYLSULFONYLACETIC ACID;2-(4-Methoxy-3-nitrobenzylsulfonyl)acetic acid;4-Methoxy-3-nitrobenzylsulfonylacetic acid;2-(4-Methoxy-3-nitrobenzylsulfonyl);3-NITRO-4-MITHOXY BENZYL SULFONYL ACETIC ACID;3-Nitro-4-methoxy benzoyl sulfonyl acetic acid
• CAS NO: 592542-51-3
• Molecular Formula: C₁₀H₁₁NO₇S
• Molecular Weight: 289.26
• EINECS: 1312995-182-4
• Mol File: 592542-51-3.mol

Chemical Properties

• Melting Point: 137-139 °C
• Boiling Point: 627.1 °C at 760 mmHg
• Flash Point: 333 °C
• Appearance: /
• Density: 1.520
• Vapor Pressure: 1.37E-16mmHg at 25°C
• Refractive Index: 1.582
• Storage Temp.: 2-8°C
• PKA: 2.39±0.10(Predicted)
• CAS DataBase Reference: 4-Methoxy-3-nitrobenzylsulfonylacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxy-3-nitrobenzylsulfonylacetic acid(592542-51-3)
• EPA Substance Registry System: 4-Methoxy-3-nitrobenzylsulfonylacetic acid(592542-51-3)

Safety Data

• Hazardous Substances Data: 592542-51-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-Methoxy-3-nitrobenzylsulfonylacetic acid is utilized as a reagent in organic synthesis for its unique chemical properties, facilitating the creation of various complex organic molecules and contributing to the advancement of chemical research.
Used in Pharmaceutical Development:
As a potential antihypertensive agent, 4-Methoxy-3-nitrobenzylsulfonylacetic acid is used in the development of new drugs for the treatment of high blood pressure. Its pharmacological properties are being studied to understand its effects on blood pressure regulation and its potential as a therapeutic intervention.
Used in Medicinal Research:
4-Methoxy-3-nitrobenzylsulfonylacetic acid is employed in medicinal research to explore its biological activities and potential applications in treating various health conditions. Its chemical structure provides a foundation for further modification and optimization to enhance its therapeutic efficacy.

InChI:InChI=1/C10H11NO7S/c1-18-9-3-2-7(4-8(9)11(14)15)5-19(16,17)6-10(12)13/h2-4H,5-6H2,1H3,(H,12,13)

Upstream product

• 6378-19-4 4-methoxy-3-nitrobenzyl chloride 
• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 41870-24-0 (4-methoxy-3-nitrophenyl)methanol 
• 119-10-8 4-methoxy-3-nitrotoluene 
• 61010-34-2 3-nitro-4-methoxybenzyl bromide 
• 34722-37-7 (4-methoxy-benzylsulfanyl)-acetic acid 
• 22216-44-0 2-(4-methoxy-3-nitrobenzylthio)acetic acid 

Downstream Products

• 1310065-00-9 2-(4-methoxy-3-nitrobenzylsulfonyl)acetyl chloride 
• 1310064-99-3 C₂₃H₂₉NO₈S 
• 592542-50-2 (E)-2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)aniline 
• 1310064-87-9 C₁₉H₂₃NO₆S 
• 1310064-89-1 C₁₈H₂₁NO₅S 
• 592542-78-4 (E)-2,4,6-trimethoxystyryl-3-(acetamido)-4-methoxybenzylsulfone 
• 1310064-86-8 C₁₈H₁₉NO₇S 
• 1310064-85-7 (E)-2',6'-dimethoxystyryl-4-methoxy-3-nitrobenzylsulfone 
• 1310064-84-6 C₁₉H₂₁NO₈S 
• 1225650-58-7 rigosertib 

Relevant articles and documents

Method for preparing new anti-tumor drug Rigosertib

The invention relates to a method for preparing new anti-tumor drug Rigosertib. By adopting the method provided by the invention, the post-treatment of each step is simple to operate, the target product can be obtained, and the operability of industrial p

Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance

Inhibiting/disturbing the RAS/RAF pathway may benefit the treatment of cancer and overcome the resistance. Utilizing such a pathway as the target, nine styrylbenzylsulfone derivatives generated from the platinum-based modification of the side chain of Rig

Design, synthesis and evaluation of 3-substituted coumarin derivatives as anti-inflammatory agents

Coumarin moiety has garnered momentous attention especially in the design of compounds with significant biological activities. In this work, a series of 3-substituted coumarin derivatives 6a-6l were synthesized and fully characterized. Most of the compoun

Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7- oxo-7,8-dihydro-pyrido[2,3- d ]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)

The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure-activity relationship trends that can be exploited in the design of potent kinase inhibitors. One compound, 8-cyclopentyl-2-[4-(4-methyl- piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6- carbonitrile (7x), was found to be the most active, inducing apoptosis of tumor cells at a concentration of approximately 30-100 nM. In vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity against the CDK4/CYCLIN D1 and ARK5 kinases. Here, we report the synthesis, structure-activity relationship, kinase inhibitory profile, in vitro cytotoxicity, and in vivo tumor regression studies by this lead compound.

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity

Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2′,4′,6′- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) associated with aberrant expression of cyclin D proteins.

Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors

We herein report the synthesis, biological activity and structure activity relationship of derivatives of benzylstyrylsulfone, benzylstyrylsulfine and benzylsulfonyl-N-phenylacetamide. A lead compound 7 represents a new class of mitotic inhibitors that demonstrates potent anti-proliferative activity and selectively induces cancer cell apoptosis while sparing non-transformed lung fibroblast.

COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA

Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.

COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA

Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: (I) wherein R1 is selected from the group consisting of -NH2, -NH-CH2-CO2H, -NH-CH(CH3)-CO2H, and -NH-C(CH3)2-CO2H, or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.

ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS

Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND- HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions.

COMPOSITION AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula (I), wherein R1 is selected from the group consisting of -OH, -NH2, -NH-CH2